簡易檢索 / 詳目顯示

研究生: 黃胤榮
Yin-Jung Huang
論文名稱: 人類海藻糖水解酶在大腸桿菌中的功能性表現與新型海藻糖水解酶抑制劑的檢測
Functional expression of human trehalase in Escherichia coli and identification of novel trehalase inhibitors
指導教授: 李冠群
Lee, Guan-Chiun
學位類別: 碩士
Master
系所名稱: 生命科學系
Department of Life Science
論文出版年: 2013
畢業學年度: 101
語文別: 中文
論文頁數: 143
中文關鍵詞: 海藻糖海藻糖水解酶海藻醣水解酶抑制劑重組蛋白質表達
英文關鍵詞: trehalose, trehalase, trehalase inhibitor, recombinant protein expression
論文種類: 學術論文
相關次數: 點閱:81下載:7
分享至:
查詢本校圖書館目錄 查詢臺灣博碩士論文知識加值系統 勘誤回報
  • 海藻糖水解酶、蔗糖酶-異麥芽糖 (sucrase-isomaltase, SI)、麥芽糖酶-葡萄糖澱粉酶 (maltase-glucoamylase, MG) 是哺乳類小腸絨毛膜主要的α-葡萄糖苷酶 (α-glucosidases),這些酵素負責把雙醣水解成單醣,以利吸收作為能量的來源。海藻糖存在於很多食物當中,而小腸海藻糖水解酶 (EC 3.2.1.28) 會水解海藻糖 (1-α-D-glucopyranosyl α-D-glucopyranoside) 成為兩個葡萄糖分子。海藻糖對細胞有兩種保護的特性,亦即可當作化學伴護劑 (Chemical chaperone) 及細胞自噬反應引發劑 (inducer of autophagy),實驗證實在神經細胞當中是可以運用在因蛋白質沉澱所造成的退化性神經疾病的藥物治療上。因此,如果能透過抑制腸道內的海藻糖水解酶活性,進而增加腸道內海藻糖吸收的話,這樣在血液和大腦中的海藻糖濃度也會增加,有可能改善由蛋白質沉澱所造成的退化性神經疾病。而人類海藻糖水解酶的結構、催化機制與其抑制劑到目前為止還沒有被研究清楚,本研究將人類海藻糖水解酶的cDNA在大腸桿菌裡表達,然而表達出來的重組蛋白質為內聚體 (inclusion body),利用透析式摺疊 (Dialysis refolding) 和管柱色層層析摺疊法 (On-column refolding) 進行蛋白質再摺疊復性,但是再摺疊出來的重組蛋白質活性非常低。為了避免因蛋白分子間及分子內不正常的雙硫鍵形成而造成蛋白質錯誤的摺疊,以增加它的可溶性,根據三級結構的模擬把人類海藻糖水解酶中可能不涉及形成雙硫鍵的半胱胺酸 (cysteine) 殘基,利用定位突變法以絲氨酸 (serine) 來取代,其中預測出4個彼此距離較遠、較不可能形成雙硫鍵的半胱胺酸,並將它們突變為絲氨酸。然而突變的重組蛋白質仍為內聚體,而且再摺疊出來的重組蛋白質仍然沒有活性。另外,生化分析數種海藻糖的結構類似物對於豬的海藻糖水解酶的抑制作用,確定可以作為哺乳類海藻糖水解酶的抑制劑,這些類似物有可能作為治療由蛋白質沉澱所造成的神經性退化性疾病的藥物。
    關鍵字: 海藻糖、海藻糖水解酶、海藻醣水解酶抑制劑、重組蛋白質表達

    In mammals, trehalase, sucrase-isomaltase and maltase-glucoamylase are the major α-glycosidases of the intestinal brush border membranes. These enzymes are responsible for the degradation of di- and oligosaccharides into monosaccharides, and are crucial for the energy-intake. Trehalase (EC 3.2.1.28) hydrolyses α,α-trehalose (1-α-D-glucopyranosyl α-D-glucopyranoside) to two glucose molecules. The intestinal trehalase is involved in the hydrolysis of ingested trehalose which is found mainly in many nutrient foods. The dual protective properties of trehalose (as a chemical chaperone and an inducer of autophagy) have encouraged pharmaceutical application of the disaccharide in neurodegenerative diseases caused by protein aggregation process. Therefore, it is theoretically possible to increase intestinal absorption of trehalose through inhibiting intestinal trehalase activity, and thus increase in trehalose content in blood or brain. This may in turn alleviate neurological protein deposition diseases. The protein structure, catalytic mechanism and specific inhibitors of human intestinal trehalase (hTreH) have not been elucidated. In the present study, a cDNA fragment encoding the mature form of hTreH was cloned and recombinant hTreH was expressed in Escherichia coli. However,the recombinant hTreH was expressed as an inclusion body. Protein refolding through dialysis and on-column refolding process were performed. The refolded enzyme showed very low specific activity. To prevent protein misfolding through the formation of incorrect intra- or inter-molecular disulfide bonds and thus increase its solubility, based on tertiary structure modeling, several predicted non-disulfide-bonding cysteine residues in hTreH were replaced with serine by site-directed mutagenesis. Four cysteine residues in hTreH were changed into serine, which are predicted to be distant from each other and may not form disulfide bonds with each other. However, the mutant proteins were also expressed as inclusion bodies, and the refolded enzymes still showed no activity. Several trehalose analogs were biochemically characterized as mammalian trehalase inhibitors, and they can be as potential therapeutics for the protein deposition-mediated diseases.
    Keyword: trehalose, trehalase, trehalase inhibitor, recombinant protein expression

    圖目錄..................................................VII 附錄....................................................XII 摘要...................................................XIII Abstract................................................XV 壹、緒論(Introduction)....................................1 一、海藻糖的簡介..........................................1 二、海藻糖水解酶的相關研究.............................. ...3 三、人類海藻糖水解酶(Human trehalase)的相關研究..............9 四、海藻糖水解酶的抑制劑...................................10 五、蛋白質的結構..........................................16 六、蛋白質的變性..........................................19 貳、研究目的(Aim)..........................................25 參、研究材料與方法 (Materials and Methods)..................26 一、使用菌體.............................................26 二、Human trehalase的基因重組載體之建構....................26 三、宿主篩檢模式之建立與評估................................35 四、Human trehalase重組蛋白質的大量表達與誘導條件............36 五、Human trehalase (isoform 2)野生型與(C28/34/175/202S)突變株的純化..................................................39 六、Human trehalase重組蛋白質的重新摺疊方法 (Protein refolding) .........................................................40 七、蛋白質電泳分析........................................48 八、Human trehalase重組蛋白質的活性測定分析.................51 九、Human trehalase之胺基酸序列分析及三級結構和DBCP雙硫鍵的預測 ..........................................................54 十、豬腎臟的海藻糖水解酶與海藻糖類似物的抑制劑實驗...............54 肆、研究結果(Results).......................................56 一、Human trehalase的基因重組載體之建構.....................56 1. Human trehalase基因的重組質體 (isoform 1).............56 2. Human trehalase基因的重組質體 (isoform 2).............56 3. Human trehalase (isoform 2) 基因的定位突變............56 二、重組蛋白質大量表達的誘導表現..............................57 pTriEx system.........................................57 1. Human trehalase (isoform 1) 野生型於大腸桿菌中的表達 ..........................................................57 pET-23a system........................................57 1. Human trehalase (isoform 1) 野生型於大腸桿菌中的表達 ..........................................................57 2. Human trehalase (isoform 2) 野生型與突變株於大腸桿菌中的表達........................................................58 三、Human trehalase (isoform 2) 野生型與 (C28/34/175/202S) 突變株的純化................................................60 四、Human trehalase重組蛋白質的重新摺疊方法 (Protein refolding) ..........................................................60 1. 利用透析式摺疊 (Dialysis refolding) 來進行蛋白質復性.....60 2. 利用色層層析摺疊法 (On-column refolding) 來進行蛋白質復性 ..........................................................61 五、Human trehalase蛋白質的HPLC活性分析....................62 1. 用8 M Urea來進行蛋白質復性後的活性分析...................62 2. 用N-Lauroylsarcosine來進行蛋白質復性後的活性分析.........62 3. 用8 M Urea+1.2 mM CTAB來進行蛋白質復性純化後的活性分析....62 4. 用8 M Urea+20 mM 2-ME來進行蛋白質復性後的活性分析........63 六、Human trehalase之胺基酸序列分析及三級結構和DBCP雙硫鍵的預測 ..........................................................63 七、豬腎臟的海藻糖水解酶與海藻糖類似物的抑制劑實驗...............63 伍、討論(discussion).......................................66 一、重組蛋白大量表達的誘導表現...............................66 二、Human trehalase (isoform 2) 野生型與 (C28/34/175/202S) 突變株的純化................................................66 三、Human trehalase重組蛋白質的重新摺疊方法 (protein refolding) ..........................................................67 四、Human trehalase之胺基酸序列分析及三級結構和DBCP雙硫鍵的預測 ..........................................................68 五、豬腎臟的海藻糖水解酶與海藻糖類似物的抑制劑影響...............69 陸、參考文獻(References)....................................70

    Asano, N., Kato, A. and Matsui, K. (1996) Two subsites on the active center of pig kidney trehalase, European Journal of Biochemistry, 240, 692-698.
    Benaroudj, N., Lee, D.H. and Goldberg, A.L. (2001) Trehalose accumulation during cellular stress protects cells and cellular proteins from damage by oxygen radicals, Journal of Biological Chemistry, 276, 24261-24267.
    Cao, G., et al. (2011) A modified electro-transformation method for Bacillus subtilis and its application in the production of antimicrobial lipopeptides, Biotechnology letters, 33, 1047-1051.
    Casarejos, M.J., et al. (2011) The accumulation of neurotoxic proteins, induced by proteasome inhibition, is reverted by trehalose, an enhancer of autophagy, in human neuroblastoma cells, Neurochem Int, 58, 512-520.
    Chen, Y. and Leong, S.S. (2009) Adsorptive refolding of a highly disulfide-bonded inclusion body protein using anion-exchange chromatography, Journal of chromatography. A, 1216, 4877-4886.
    Chiara, J.L., et al. (2005) Synthesis, inhibition properties, and theoretical study of the new nanomolar trehalase inhibitor 1-thiatrehazolin: towards a structural understanding of trehazolin inhibition, Chembiochem : a European journal of chemical biology, 6, 186-191.
    de Almeida, F.M., et al. (2009) Heterologous expression in Escherichia coli of Neurospora crassa neutral trehalase as an active enzyme, Protein expression and purification, 65, 185-189.
    Ganzle, M.G., Haase, G. and Jelen, P. (2008) Lactose: Crystallization, hydrolysis and value-added derivatives, Int Dairy J, 18, 685-694.
    Gibson, R.P., et al. (2007) Molecular basis for trehalase inhibition revealed by the structure of trehalase in complex with potent inhibitors, Angew Chem Int Ed Engl, 46, 4115-4119.
    Guo, M.X., Wrisley, L. and Maygoo, E. (2006) Measurement of tobramycin by reversed-phase high-performance liquid chromatography with mass spectrometry detection, Analytica chimica acta, 571, 12-16.
    Ishihara, R., et al. (1997) Molecular cloning, sequencing and expression of cDNA encoding human trehalase, Gene, 202, 69-74.
    Kiefhaber, T., et al. (1991) Protein Aggregation Invitro and Invivo - a Quantitative Model of the Kinetic Competition between Folding and Aggregation, Bio-Technol, 9, 825-829.
    Lee, S.B., Park, K.H. and Robyt, J.F. (2001) Inhibition of beta-glycosidases by acarbose analogues containing cellobiose and lactose structures, Carbohydrate research, 331, 13-18.
    Li, M., Su, Z.G. and Janson, J.C. (2004) In vitro protein refolding by chromatographic procedures, Protein expression and purification, 33, 1-10.
    Lina, B.A.R., Jonker, D. and Kozianowski, G. (2002) Isomaltulose (Palatinose (R)): a review of biological and toxicological studies, Food Chem Toxicol, 40, 1375-1381.
    Matsuo, T., Tsuchida, Y. and Morimoto, N. (2002) Trehalose eye drops in the treatment of dry eye syndrome, Ophthalmology, 109, 2024-2029.
    Mori, H., et al. (2009) Catalytic reaction mechanism based on alpha-secondary deuterium isotope effects in hydrolysis of trehalose by European honeybee trehalase, Bioscience, biotechnology, and biochemistry, 73, 2466-2473.
    Oesterreicher, T.J., Markesich, D.C. and Henning, S.J. (2001) Cloning, characterization and mapping of the mouse trehalase (Treh) gene, Gene, 270, 211-220.
    Panesar, P.S. and Kumari, S. (2011) Lactulose: production, purification and potential applications, Biotechnology advances, 29, 940-948.
    Puius, Y.A., Stievater, T.H. and Srikrishnan, T. (2006) Crystal structure, conformation, and absolute configuration of kanamycin A, Carbohydrate research, 341, 2871-2875.
    Richards, A.B., et al. (2002) Trehalose: a review of properties, history of use and human tolerance, and results of multiple safety studies, Food Chem Toxicol, 40, 871-898.
    Richards, A.B., et al. (2002) Trehalose: a review of properties, history of use and human tolerance, and results of multiple safety studies, Food Chem Toxicol, 40, 871-898.
    Rodriguez-Navarro, J.A., et al. (2010) Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation, Neurobiology of disease, 39, 423-438.
    Schlegl, R., et al. (2003) Continuous matrix-assisted refolding of proteins, Journal of chromatography. A, 1009, 119-132.
    Silva, M.C.P., Terra, W.R. and Ferreira, C. (2010) The catalytic and other residues essential for the activity of the midgut trehalase from Spodoptera frugiperda, Insect biochemistry and molecular biology, 40, 733-741.
    Spiess, A.N. and Ivell, R. (2002) A highly efficient method for long-chain cDNA synthesis using trehalose and betaine, Analytical biochemistry, 301, 168-174.
    Tomita, K., et al. (2007) Dietary melibiose regulates th cell response and enhances the induction of oral tolerance, Bioscience, biotechnology, and biochemistry, 71, 2774-2780.
    Van Beers, E.H., et al. (1995) Intestinal brush border glycohydrolases: structure, function, and development, Critical reviews in biochemistry and molecular biology, 30, 197-262.
    Vigil, C.E., Martin-Santos, T. and Garcia-Manero, G. (2010) Safety and efficacy of azacitidine in myelodysplastic syndromes, Drug design, development and therapy, 4, 221-229.
    Willms, B. and Ruge, D. (1999) Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study, Diabetic Med, 16, 755-761.
    Wind, J., Smeekens, S. and Hanson, J. (2010) Sucrose: metabolite and signaling molecule, Phytochemistry, 71, 1610-1614.

    下載圖示
    QR CODE